Unlocking new possibilities for the treatment of fibrotic diseases
Explore Our Science
Endeavor BioMedicines is a clinical-stage biotechnology company focused on developing medicines for the treatment of fibrotic diseases with high unmet need. By unlocking the therapeutic potential of the Hedgehog (Hh) signaling pathway, Endeavor is advancing a new approach to addressing fibrosis across organ systems. The company’s initial focus is on the development of its lead investigational candidate, taladegib (ENV-101), an inhibitor of the Hh signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF).
OUR SCIENCE
Our scientific research is focused on addressing the biology that drives fibrotic disease progression. The Hedgehog signaling pathway represents a novel approach to target the causative cellular drivers of fibrotic diseases.
Our leadership team has deep experience in translating scientific innovation into medicines that make a meaningful difference for patients, including those affected by serious diseases with high unmet need.
OUR LEADERSHIP
OUR CULTURE
We have a vibrant and passionate culture that reflects our shared mission to deliver new therapeutic options for patients affected by serious diseases with high unmet need.
LATEST NEWS
Endeavor BioMedicines to Present Quantitative Image Analysis from Phase 2a Trial of Taladegib (ENV-101) at European Respiratory Society (ERS) Congress 2026
SAN DIEGO – August 25, 2026 – Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that results from a High-Resolution Computed Tomography (HRCT) post hoc analysis from its Phase 2a trial evaluating taladegib (ENV-101) in...
Endeavor BioMedicines Receives Priority Medicines (PRIME) Designation from the European Medicines Agency for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
Taladegib is the first and only investigational IPF therapy to receive PRIME designation Phase 2b WHISTLE-PF trial is on track to complete enrollment in H1 2026 SAN DIEGO – November 3, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational benefits to patients with life-threatening...
Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Evaluating taladegib (ENV-101) in Individuals with Idiopathic Pulmonary Fibrosis
Treatment with taladegib demonstrated improved lung function from baseline, increased total lung capacity and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis Data also presented today in ALERT session at European Respiratory Society (ERS) Congress 2025 The between-group difference from baseline to week 12 in percent predicted forced...
Fibrotic Lung Disease
Phase 2a findings in idiopathic pulmonary fibrosis provide clinical proof of concept for taladegib and support continued investigation of Hedgehog pathway inhibition as a potential approach to addressing fibrosis.